A longitudinal population-based study of prothrombotic factors in elderly subjects with atrial fibrillation: The Rotterdam Study 1990-1999

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 9, 2006, Pages 1944-1949

  Heeringa, J ^a   Conway, D S G ^b   Van der Kuip, D A M ^a   Hofman, A ^a   Breteler, M M B ^a   Lip, G Y H ^b   Witteman, Jacqueline C M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CITY HOSPITAL   (United Kingdom)

Author keywords

Atrial fibrillation; Cardiac mortality; Epidemiology; Prothrombotic state; Stroke

Indexed keywords

BLOOD CLOTTING FACTOR; FIBRINOGEN; PADGEM PROTEIN; VON WILLEBRAND FACTOR;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENDER; HEART ATRIUM FIBRILLATION; HEART DISEASE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NETHERLANDS; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK FACTOR; SINUS RHYTHM; STATISTICAL SIGNIFICANCE; STROKE; THROMBOCYTE;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; BLOOD COAGULATION FACTORS; CASE-CONTROL STUDIES; CEREBROVASCULAR ACCIDENT; COHORT STUDIES; DEATH; FEMALE; FIBRINOGEN; HUMANS; LONGITUDINAL STUDIES; MALE; NETHERLANDS; P-SELECTIN; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; STROKE; THROMBOPHILIA; THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 33747198470     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.02115.x     Document Type: Article

References (34)

1. Wolf PA, Abbott RD, Kannel WB, eds. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991; 22: 983-8.
2. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82: 2N-9N.
3. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998; 98: 946-52.
4. Frost L, Engholm G, Johnson S, Moller H, Henneberg EW, Husted S. Incident thromboembolism in the aorta and the renal, mesenteric, pelvic, and extremity arteries after discharge from the hospital with a diagnosis of atrial fibrillation. Arch Intern Med 2001; 161: 272-6.
5. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Ann Intern Med 1999; 131: 492-501.
6. Lip GY, Hart RG, Conway DS. Antithrombotic therapy for atrial fibrillation. BMJ 2002; 325: 1022-5.
7. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87: 144-52.
8. Lip GY. Does atrial fibrillation confer a hypercoagulable state ? Lancet 1995; 346: 1313-4.
9. Heppell RM, Berkin KE, McLenachan JM, Davies JA. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. Heart 1997; 77: 407-11.
10. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003; 107: 3141-5.
11. Blann AD, Nadar SK, Lip GY. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 2003; 24: 2166-79.
12. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: The Rotterdam Elderly Study. Eur J Epidemiol 1991; 7: 403-22.
13. van Bemmel JH, Kors JA, van Herpen G. Methodology of the modular ECG analysis system MEANS. Methods Inf Med 1990; 29: 346-53.
14. Kors JA, van Herpen G, Wu J, Zhang Z, Prineas RJ, van Bemmel JH. Validation of a new computer program for Minnesota coding. J Electrocardiol 1996; 29: 83-8.
15. Meade TW, Cooper JA, Stirling Y, Howarth DJ, Ruddock V, Miller GJ. Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br J Haematol 1994; 88: 601-7.
16. Smith FB, Lee AJ, Fowkes FG, Price JF, Rumley A, Lowe GD. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1997; 17: 3321-5.
17. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997; 96: 1102-8.
18. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332: 635-41.
19. Conway DS, Heeringa J, Van Der Kuip DA, Chin BS, Hofman A, Witteman JC, Lip GYH. Atrial fibrillation and the prothrombotic state in the elderly: the Rotterdam Study. Stroke 2003; 34: 413-7.
20. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001; 103: 491-5.
21. Malik I, Danesh J, Whincup P, Bhatia V, Papacosta O, Walker M, Lennon L, Thomson A. Soluble adhesion molecules and prediction of coronary heart disease: A prospective study and meta-analysis. Lancet 2001; 358: 971-6.
22. Kamath S, Blann AD, Lip GY. Platelets and atrial fibrillation. Eur Heart J 2001; 22: 2233-42.
23. Feinberg WM, Pearce LA, Hart RG, Cushman M, Cornell ES, Lip GY, Bovill EG, for the Stroke Prevention in Atrial Fibrillation Investigators. Markers of thrombin and platelet activity in patients with atrial fibrillation: Correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. Stroke 1999; 30: 2547-53.
24. Conway DS, Lip GY. Atrial physiology. In: Lip GYH, Godtfredsen J, eds. Cardiac Arrhythmias: A Clinical Approach. Edinburgh: Mosby, 2003: 25-45.
25. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-9.
26. Ma J, Hennekens CH, Ridker PM, Stampfer MJ. A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health Study. J Am Coll Cardiol 1999; 33: 1347-52.
27. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies. JAMA 1998; 279: 1477-82.
28. Ridker PM. Role of inflammatory biomarkers in prediction of coronary heart disease. Lancet 2001; 358: 946-8.
29. Tracy RP, Arnold AM, Ettinger W, Fried L, Meilahn E, Savage P. The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: Results from the cardiovascular health study. Arterioscler Thromb Vasc Biol 1999; 19: 1776-83.
30. Feng D, D'Agostino RB, Silbershatz H, Lipinska I, Massaro J, Levy D, Benjamin EJ, Wolf PA, Tofler GH. Hemostatic state and atrial fibrillation (the Framingham Offspring Study). Am J Cardiol 2001; 87: 168-71.
31. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors. Circulation 2002; 106: 1962-7.
32. Chung NA, Belgore F, Li-Saw-Hee FL, Conway DS, Blann AD, Lip GY. Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor ? Stroke 2002; 33: 2187-91.
33. Conway DS, Buggins P, Hughes E, Lip GY. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol 2004; 43: 2075-82.
34. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, Tracy RP, Van Wagoner DR, Psaty BM, Lauer MS, Chung MK. Inflammation as a risk factor for atrial fibrillation. Circulation 2003; 108: 3006-10.